ÂÜÀòÂÒÂ×

Dr. Seto has over 25 years of experience in oncology research specializing in medical oncology for thoracic malignancies. Conducting clinical trials with new agents has been his primary focus for the past 15 years at the National Kyushu Cancer Center. His tenure also includes Kumamoto Regional Medical Center and Tokai University Hospital. He joined Precision Medicine Asia (PREMIA) in September 2019 to focus on the development of precision medicine and targeted new drug therapies.

Dr. Seto is a member of the International Association for Study of Lung Cancer (IASLC, Board of Directors), the American Society for Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), and the Japan Society of Medical Oncology (JSMO, Councilor), and the Japan Lung Cancer Society (JLCS, Councilor). In 2005, Dr. Seto was involved with the revision of the JLCS Practice Guideline and from 2014 to 2018, served as Chief of Medical Oncology and Multidisciplinary Therapy. He is also an active member of the Japan Clinical Oncology Group (JCOG) and a member and board member of the West Japan Oncology Group (WJOG).

Dr. Seto graduated from Kurume University School of Medicine in 1990.